Willie Reed - Zoetis Independent Director

ZTS -- USA Stock  

Quarterly Earning Report: November 7, 2019  

  Director
Dr. Willie M. Reed is Independent Director of the Company. Dr. Reed has more than 30 years of experience in animal health and veterinary medicine, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians. Dr. Reed has served as President of the Association of American Veterinary Medical Colleges, President of the American Association of Veterinary Laboratory Diagnosticians, President of the American Association of Avian Pathologists and Chair of the American Veterinary Medical Association Council on Research. He has served on a number of committees for the National Institutes of Health and the United States Department of Agriculture. Dr. Reed has a DVM from Tuskegee University, and a Ph.D. in Veterinary Pathology from Purdue University. Dr. Reeds expertise in veterinary medicines and vaccines and his thought leadership in the animal health community make him a valuable member of our Board.
Age: 63  Director Since 2014  Ph.D    
973 822-7000  www.zoetis.com
Reed has a Doctor of Veterinary Medicine degree from Tuskegee University, and a Ph.D. in Veterinary Pathology from Purdue University.

Willie Reed Latest Insider Activity

Willie Reed over three months ago via Macroaxis 
Sale by Willie Reed of 1900 shares of Zoetis

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65 B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Min TangOrigin Agritech Limited
2009
Alfred GilmanRegeneron Pharmaceuticals
1990
Alan GarberVertex Pharmaceuticals Incorpor
2017
Ellen HoffingPerrigo Company Plc
2008
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Adriana KaraboutisPerrigo Company Plc
2017
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Prasad MenonDr Reddys Laboratories Ltd
2019
Theodore SamuelsPerrigo Company Plc
2017
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Leo PuriDr Reddys Laboratories Ltd
2018
Hans HaslerDr Reddys Laboratories Ltd
2016
Christine PoonRegeneron Pharmaceuticals
2010
Charles BakerRegeneron Pharmaceuticals
N/A
Bruce CarterDr Reddys Laboratories Ltd
2008
Rolf ClassonPerrigo Company Plc
2017
Huda ZoghbiRegeneron Pharmaceuticals
2016
Bruce SachsVertex Pharmaceuticals Incorpor
2017
William YoungVertex Pharmaceuticals Incorpor
2014
Herman MorrisPerrigo Company Plc
1999
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased few shares of
3 hours ago
Traded for 1243.01
Purchased over 40 shares of
3 hours ago
Traded for 65.56
Purchased over 20 shares of
3 hours ago
Traded for 141.57
See also Your Current Watchlist. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Search macroaxis.com